Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones

Journal of Cataract and Refractive Surgery

Volumn 36, Issue 9, 2010, Pages 1588-1598

  McDonald, Marguerite ^a,b   Blondeau, Joseph M ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLOROFLUOROQUINOLONE; 8 METHOXY FLUOROQUINOLONE DERIVATIVE; AMINOGLYCOSIDE; AZITHROMYCIN; BENZALKONIUM CHLORIDE; BESIFLOXACIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; METICILLIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN G; POLYMYXIN B; QUINOLONE DERIVATIVE; SULFONAMIDE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL STRAIN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EYE INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; BACTERIA; BACTERIAL EYE INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 77955589135     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2010.06.028     Document Type: Article

References (66)

1. P.H. Blomquist Methicillin-resistant Staphylococcus aureus infections of the eye and orbit Trans Am Ophthalmol Soc 104 2006 322 345 Available at: http://www.aosonline.org/xactions/2006/1545-6110-v104-p322.pdf Accessed May 23, 2010
2. S.D. Brown, and M.J. Rybak Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study J Antimicrob Chemother 54 suppl S1 2004 i7 i15 Available at: http://jac. oxfordjournals.org/cgi/reprint/54/suppl-1/i7 Accessed May 27, 2010
3. M.R. Jacobs, D. Felmingham, P.C. Appelbaum, and R.N. Grüneberg The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infections to commonly used antimicrobial agents; the Alexander Project Group J Antimicrob Chemother 52 2003 229 246 Available at: http://jac.oxfordjournals.org/cgi/reprint/52/2/229 Accessed May 27, 2010
4. L.M. Deshpande, T.R. Fritsche, G.J. Moet, D.J. Biedenbach, and R.N. Jones Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY Antimicrobial Surveillance Program Diagn Microbiol Infect Dis 58 2007 163 170
5. D.M. Johnson, M.G. Stilwell, T.R. Fritsche, and R.N. Jones Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003) Diagn Microbiol Infect Dis 56 2006 69 74
6. P.A. Asbell, K.A. Colby, S. Deng, P. McDonnell, D.M. Meisler, M.B. Raizman, J.D. Sheppard Jr., and D.F. Sahm Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates Am J Ophthalmol 145 2008 951 958
7. P.A. Asbell, D.F. Sahm, M. Shaw, D.C. Draghi, and N.P. Brown Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005 J Cataract Refract Surg 34 2008 814 818
8. D.M. Miller, A.S. Vedula, H.W. Flynn Jr., D. Miller, I.U. Scott, W.E. Smiddy, T.G. Murray, and A.S. Venkatraman Endophthalmitis caused by Staphylococcus epidermidis: in vitro antibiotic susceptibilities and clinical outcomes Ophthalmol Surg Lasers Imaging 38 2007 446 451
9. Centers for Disease Control and Prevention Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae - Massachusetts, 2001-2006 MMWR 56 2007 1077 1080 Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5641a2.htm Accessed May 27, 2010
10. L.B. Rice The clinical consequences of antimicrobial resistance Curr Opin Microbiol 12 2009 476 481
11. E. Klein, D.L. Smith, and R. Laxminarayan Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 Emerg Infect Dis 13 2007 1840 1846 Available at: http://www.cdc.gov/eid/content/ 13/12/pdfs/1840.pdf Accessed May 27, 2010
12. R.M. Klevens, M.A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L.H. Harrison, R. Lynfield, G. Dumyati, J.M. Townes, A.S. Craig, E.R. Zell, G.E. Fosheim, L.K. McDougal, R.B. Carey, and S.K. Fridkin Invasive methicillin-resistant Staphylococcus aureus infections in the United States; the Active Bacterial Core surveillance (ABCs) MRSA Investigators JAMA 298 2007 1763 1771
13. J.D. Siegel, E. Rhinehart, M. Jackson, L. Chiarello Atlanta, GA Management of multidrug-resistant organisms in healthcare settings 2006 Centers for Disease Control and Prevention Available at: http://www.cdc.gov/ncidod/dhqp/ pdf/ar/mdroguideline2006.pdf Accessed May 23, 2010
14. G. Høvding Acute bacterial conjunctivitis Acta Ophthalmol (Oxf) 86 2008 5 17
15. A. Sheikh, and B. Hurwitz Antibiotics versus placebo for acute bacterial conjunctivitis Cochrane Database Syst Rev 2 2006 CD001211
16. K. Todar Bacterial resistance to antibiotics Todar's Online Textbook of Bacteriology 2008 University of Wisconsin-Madison Department of Bacteriology Madison, WI Available at: http://www.textbookofbacteriology.net/ resantimicrobial.html Accessed May 23, 2010
17. C.W. Stratton Mechanisms of bacterial resistance to antimicrobial agents J Med Liban 48 2000 186 198
18. F.C. Tenover Mechanisms of antimicrobial resistance in bacteria Am J Infect Control 34 5, suppl 1 2006 S3 S10
19. E.Y. Ng, M. Trucksis, and D.C. Hooper Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus Antimicrob Agents Chemother 40 1996 1881 1888 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC163434/pdf/ 401881.pdf Accessed May 23, 2010
20. R. Leclercg, and P. Courvalin Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification Antimicrob Agents Chemother 35 1991 1267 1272 Avail-able at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC245156/pdf/aac00051-0031.pdf Correction available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC245349/?page=1 Accessed May 27, 2010
21. S.P. Cohen, L.M. McMurry, and S.B. Levy marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (mar) mutants of Escherichia coli J Bacteriol 170 1988 5416 5422 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC211632/pdf/jbacter00190-0024.pdf Accessed May 23, 2010
22. G.G. Zhanel, D.J. Hoban, K. Schurek, and J.A. Karlowsky Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa Int J Antimicrob Agents 24 2004 529 535
23. D.G. Hwang Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones Surv Ophthalmol 49 suppl 2 2004 S79 S83
24. D. Cheng, W.-R. Xu, and C.-X. Liu Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials World J Gastroenterol 13 2007 2496 2503 Available at: http://www.wjgnet.com/1007-9327/13/2496.pdf Accessed May 23, 2010
25. D.C. Hooper Emerging mechanisms of fluoroquinolone resistance Emerg Infect Dis 7 2001 337 341 Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2631735/pdf/11294736.pdf Accessed May 23, 2010
26. J.M. Blondeau Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 suppl 2 2004 S73 S78
27. E. Cambau, S. Matrat, Pan X-Su, R.R.D. Bettoni, C. Corbel, A. Aubry, C. Lascols, J.-Y. Driot, and L.M. Fisher Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli J Antimicrob Chemother 63 2009 443 450 Available at: http://jac.oxfordjournals.org/cgi/reprint/63/3/443?maxtoshow=&hits= 10&RESULTFORMAT=&fulltext=cambau%2C+E&searchid=1&FIRSTINDEX= 0&resourcetype=HWCIT Accessed May 27, 2010
28. C.K. Hesje, G.S. Tillotson, and J.M. Blondeau MICs, MPCs and PK/PDs: a match (sometimes) made in hosts [editorial] Expert Rev Resp Med 1 2007 7 16
29. J.M. Blondeau, G. Hansen, K. Metzler, and P. Hedlin The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration J Chemother 16 suppl 3 2004 S1 S19
30. F. Mah The benefits of fourth generation fluoroquinolones in the prevention of ocular infections Clin Surg Ophthalmol 22 2004 228 231
31. J. Kaliamurthy, C.A.N. Jesudasan, P. Geraldine, P. Parmar, C.M. Kalavathy, and P.A. Thomas Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics Ophthalmic Res 37 2005 117 122
32. P. Parmar, A. Salman, C.M. Kalavathy, J. Kaliamurthy, D.A. Prasanth, P.A. Thomas, and C.A.N. Jesudasanl Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis Am J Ophthalmol 141 2006 282 286
33. J.M. Dargin, and R.A. Lowenstein The painful eye Emerg Med Clin North Am 26 1 2008 199 216, viii
34. M.G. Speaker, F.A. Milch, M.K. Shah, W. Eisner, and B.N. Kreiswirth Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis Ophthalmology 98 1991 639 649 discussion by J Baum, 650
35. T.L. Bannerman, D.L. Rhoden, S.K. McAllister, J.M. Miller, and L.A. Wilson The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study; a comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis; the Endophthalmitis Vitrectomy Study Group Arch Ophthalmol 115 1997 357 361 Available at: http://archopht.ama-assn.org/cgi/ reprint/115/3/357 Accessed May 27, 2010
36. D.P. Han, S.R. Wisniewski, L.A. Wilson, M. Barza, A.K. Vine, B.H. Doft, and S.F. Kelsey Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study; the Endophthalmitis Vitrectomy Study Group Am J Ophthalmol 122 1996 1 17 correction, 920
37. T.A. Ciulla, M.B. Starr, and S. Masket Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update Ophthalmology 109 2002 13 24
38. K. Cavuoto, D. Zutshi, C.L. Karp, D. Miller, and W. Feuer Update on bacterial conjunctivitis in south Florida Ophthalmology 115 2008 51 56
39. H.G. Jensen, and C. Felix In vitro antibiotic susceptibilities of ocular isolates in North and South America; the In Vitro Antibiotic Testing Group Cornea 17 1998 79 87
40. S.L. Block, J. Hedrick, R. Tyler, A. Smith, R. Findlay, E. Keegan, and D.W. Stroman Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998) Antimicrob Agents Chemother 44 2000 1650 1654 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89927/pdf/ac001650.pdf Accessed May 23, 2010
41. N. Buznach, R. Dagan, and D. Greenberg Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era Pediatr Infect Dis J 24 2005 823 828
42. I. Morrissey, R. Burnett, L. Viljoen, and M. Robbins Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002 J Infect 49 2004 109 114
43. B. Orden Martínez, R. Martínez Ruiz, and R. Millán Pérez Conjuntivitis bacteriana: patógenos más prevalentes y sensibilidad antibiótica [Bacterial conjunctivitis: most prevalent pathogens and their antibiotic sensitivity] An Pediatr (Barc) 61 2004 32 36
44. N.A. Chaudhry, H.W. Flynn Jr., T.G. Murray, H. Tabarideh, M.O. Mello Jr., and D. Miller Emerging ciprofloxacin-resistant Pseudomonas aeruginosa Am J Ophthalmol 128 1999 509 510
45. G. Alexandrakis, E.C. Alfonso, and D. Miller Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones Ophthalmology 107 2000 1497 1502
46. S.P. Epstein, E.J. Bottone, and P.A. Asbell Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infections Eye Contact Lens 32 2006 240 244
47. S.H. Park, J.-A. Lim, J.-S. Choi, K.-A. Kim, and C.-K. Joo The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics Cornea 28 2009 68 72
48. T. Harper, D. Miller, and H.W. Flynn Jr. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates Ophthalmology 114 2007 871 875
49. M.R. Chalita, A.L. Höfling-Lima, A. Paranhos Jr., P. Schor, and R. Belfort Jr. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years Am J Ophthalmol 137 2004 43 51
50. A. Pinna, S. Zanetti, M. Sotgiu, L.A. Sechi, G. Fadda, and F. Carta Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections Br J Ophthalmol 83 1999 771 773 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1723098/pdf/ v083p00771.pdf Accessed May 23, 2010
51. F.M. Recchia, B.G. Busbee, R.B. Pearlman, C.A. Carvalho-Recchia, and A.C. Ho Changing trends in the microbiologic aspects of postcataract endophthalmitis Arch Ophthalmol 123 2005 341 346
52. D. Miller, P.M. Flynn, I.U. Scott, E.C. Alfonso, and H.F. Flynn Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates Arch Ophthalmol 124 2006 479 483
53. F.B. Marangon, D. Miller, M.S. Muallem, A.C. Romano, and E.C. Alfonson Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis Am J Ophthalmol 137 2004 453 458
54. G. McDonnell, and A.D. Russell Antiseptics and disinfectants: activity, action, and resistance Clin Microb Rev 12 1999 147 179 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC88911/pdf/cm000147.pdf correction available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC88971/
55. J.M. Blondeau, S. Boros, and C.K. Hesje Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus J Chemother 19 2007 146 151
56. J.D. Bartlett, Ophthalmic Drug Facts 20th ed 2008 Wolters Kluwer Health St. Louis, MO
57. M.C. Callegan, B.D. Novosad, R.T. Ramadan, B. Wiskur, and A.L. Moyer Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones Adv Ther 26 2009 447 454
58. C.K. Hesje, S.D. Borsos, and J.M. Blondeau Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains J Ocul Pharmacol Ther 25 2009 329 334
59. F.B. Marangon, D. Miller, and E.C. Alfonso Impact of prior therapy on the recovery and frequency of corneal pathogens Cornea 23 2004 158 164
60. A.C. Croft, A.V. D'Antoni, and S.L. Terzulli Update on the antibacterial resistance crisis Med Sci Monit 13 2007 RA103 RA118
61. Miller D, Alfonso EC, "Prevalence of Community-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Among Ocular MRSAIsolates," presented at the annual meeting of the American Academy of Ophthalmology, New Orleans, Louisiana, USA, November, 2007
62. McDonald MB, Blondeau JM, DeCory HH, Usner DW, Brunner LS, Haas W, Morris TW, "Multidrug-Resistant Strains in Clinical Trials of Besifloxacin in the Treatment of Bacterial Conjunctivitis," poster presented at the annual meeting of the American Academy of Ophthalmology, Atlanta, Georgia, USA, November 2008
63. Haas W, Brunner LS, Pillar C, Zurenko GE, Lee J, Morris TW
64. J.M. Blondeau, P. Hedlin, and S.D. Borsos The antimicrobial activity of gatifloxacin (GAT) with or without benzalkonium chloride (BAK) against ocular bacterial pathogens IOVS 46 2005 ARVO E-Abstract 4880
65. S.D. Borsos, J.M. Blondeau, and C.K. Hesje Comparative in vitro potency of levofloxacin (Lfx) and gatifloxacin (Gfx) plus benzalkonium chloride (BAK) against gram-positive (GP) pathogens including methicillin-resistant Staphylococcus aureus (MRSA) IOVS 49 2008 ARVO E-Abstract 1980
66. F.S. Mah, E.G. Romanowski, R.P. Kowalski, K.A. Yates, and Y.J. Gordon Benzalkonium chloride (BAK) significantly enhances the antibacterial efficacy of gatifloxacin in the Staphylococcus aureus NZW rabbit keratitis model IOVS 47 2006 ARVO E-Abstract 1905